The increasing rates of resistance to antibiotics among gram-negative pathogens have driven the development of antibiotics that target specific mechanisms of resistance and/or bacterial species. However, due to the potency and price of these drugs, access to them frequently requires prior bacterial identification and susceptibility testing. Until recently, those procedures would require several days, delaying the time to effective therapy. However, new technologies developed or in development by Bruker, bioMérieux, T2 Biosystems, and others now allow for a significant reduction in the turnaround period and facilitate faster and more appropriate antibiotic prescribing. As a consequence, these tools offer the potential to improve outcomes and decrease the overall cost of treatment.
DRG’s Special Topics reports use quantitative and quantitative primary research to assess evolving trends and market effects in dynamic disease areas. Insights from this report on GNIs will help antibiotic and medical device developers understand current and future practices in the clinical microbiology laboratory and how they shape the uptake of current and emerging therapies.
Survey of 100 infectious diseases specialists; more than 10 interviews with thought-leading infectious diseases specialists and medical directors/directors of clinical microbiology laboratories.
KEY DRUGS COVERED
Avycaz, Zerbaxa, Vabomere, Teflaro, and other key GNI generic drugs.
KEY DIAGNOSTICS COVERED
Accelerate Pheno System, fluorescence based assays, MALDI-TOF-MS, and molecular diagnostics.
KEY INSIGHTS PROVIDED